NasdaqGS:HALOBiotechs
Does Halozyme’s Raised 2026 Revenue Outlook And Aggressive Buybacks Change The Bull Case For HALO?
In August 2026, Halozyme Therapeutics reported past second-quarter 2026 results showing revenue of US$481.00 million and net income of US$229.91 million, alongside higher earnings per share and the completion of share repurchases totaling 13,452,356 shares for US$750.00 million across two programs.
The company also raised its 2026 total revenue guidance to a range of US$1.84 billion to US$1.91 billion, indicating management’s increased confidence after strong first-half performance and...